Abstract
The outcome of cancer metastasis depends on the interaction of metastatic cells with various host factors. The implantation of human cancer cells into anatomically correct (orthotopic) sites in nude mice can be used to ascertain their metastatic potential. While it is clear that vascularity and local immunity can retard or facilitate tumor growth, we have found that the organ environment also influences tumor cell functions such as production of degradative enzymes. The organ microenvironment can also influence the response of metastases to chemotherapy. It is not uncommon to observe the regression of cancer metastases in one organ and their continued growth in other sites after systemic chemotherapy. We demonstrated this effect in a series of experiments using a murine fibrosarcoma, a murine colon carcinoma, and a human colon carcinoma. The tumor cells were implanted subcutaneously or into different visceral organs. Subcutaneous tumors were sensitive to doxorubicin (DXR), whereas lung or liver metastases were not. In contrast, sensitivity to 5-FU did not differ between these sites of growth. The differences in response to DXR between s.c. tumors (sensitive) and lung or liver tumors (resistant) were not due to variations in DXR potency or DXR distribution. The expression of the multidrug resistance-associated P-glycoprotein as determined by flow cytometric analysis of tumor cells harvested from lesions in different organs correlated inversely with their sensitivity to DXR: increased P-glycoprotein was associated with overexpression ofmdr1 mRNA. However, the organ-specific mechanism for upregulatingmdr1 and P-glycoprotein has yet to be elucidated.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Fidler IJ: Critical factors in the biology of human cancer metastasis: twenty-eight G.H.A. Clowes memorial award lecture. Cancer Res 50: 6130–6138, 1990
Fidler IJ, Poste G: The cellular heterogeneity of malignant neoplasms: implications for adjuvant chemotherapy. Semin Oncol 12: 207–221, 1985
Heppner G: Tumor heterogeneity. Cancer Res 44: 2259–2265, 1984
Dexter DL, Leith JT: Tumor heterogeneity and drug resistance. J Clin Oncol 4: 244–257, 1986
Fidler IJ, Balch CM: The biology of cancer metastasis and implications for therapy. Curr Probl Surg 24: 137–209, 1987
Paget S: The distribution of secondary growths in cancer of the breast. Lancet 1: 571–573, 1889
Fidler IJ, Kripke ML: Metastasis results from pre-existing variant cells within a malignant tumor. Science 197: 893–895, 1977
Price JE, Aukerman SL, Fidler IJ: Evidence that the process of murine melanoma metastasis is sequential and selective and contains stochastic elements. Cancer Res 46: 5172–5178, 1986
Talmadge JE, Wolman SR, Fidler IJ: Evidence for the clonal origin of spontaneous metastasis. Science 217: 361–363, 1982
Fidler IJ, Talmadge JE: Evidence that intravenously derived murine pulmonary metastases can originate from the expansion of a single tumor cell. Cancer Res 46: 5167–5171, 1986
Hart IR, Fidler IJ: Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res 41: 1281–1287, 1981
Tsuruo T, Fidler IJ: Differences in drug sensitivity among tumor cells from parental tumors, selected variants, and spontaneous metastases. Cancer Res 41: 3058–3064, 1981
Teicher BA, Herman TS, Holden SA, Wang Y, Pfeffer MR, Crawford JW, Frei E: Tumor resistance to alkylating agents conferred by mechanisms operative onlyin vivo. Science (Washington DC) 247: 1457–1461, 1990
Schneiderman MA: The clinical excursion into 5-fluorouracil. Cancer Chemother Rep 16: 107–116, 1962
Donelli MG, Rosso R, Garatini S: Selective chemotherapy in relation to the site of tumor transplantation. Int J Cancer 32: 78–86, 1975
Donelli MG, Colombo T, Broggini M, Garattini S: Differential distribution of antitumor agents in primary and secondary tumors. Cancer Treat Rep 61: 1319–1324, 1977
Slack NH, Bross JDJ: The influence of site of metastasis on tumor growth and response to chemotherapy. Br J Cancer 32: 78–86, 1975
Teicher BA, Herman TS, Holden SA, Wang Y, Pfeffer MR, Crawford JW, Frei E: Tumor resistance to alkylating agents conferred by mechanisms operative onlyin vivo. Science (Washington DC) 247: 1457–1461, 1990
Holst E, Sievers U, Schmahl D: Experimental investigations about the chemosensitivity of transplantation tumor at different sites of transplantation. Z Krebsforsch 76: 325–329, 1971
Vaupel P, Kallinowski F, Okunieff P: Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49: 6449–6465, 1989
Teicher BA, Lazo JS, Sartorelli AC: Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res 41: 73–81, 1981
Sartorelli AC: Therapeutic attack of hypoxic cells of solid tumors: presidential address. Cancer Res 48: 775–778, 1988
Moulder JE, Rockwell S: Tumor hypoxia: its impact on cancer therapy. Cancer Metastasis Rev 5: 313–341, 1987
Tannock IF, Rotin D: Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 49: 4373–4384, 1989
Boyer MJ, Barnard M, Hedley DW, Tannock IF: Regulation of intracellular pH in subpopulations of cells derived from spheroids and solid tumors. Br J Cancer 36: 890–897, 1993
Volk T, Jahde E, Fortmeyer HP, Glusenkamp K-H, Rajewsky MF: pH in human tumour xenografts: effect of intravenous administration of glucose. Br J Cancer 68: 492–500, 1993
Jain RK: Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J Natl Cancer Inst 81: 570–576, 1989
Suzuki M, Hori K, Abe I: A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II. J Natl Cancer Inst 67: 663–669, 1981
Tozer GM, Lewis S, Michalowski A, Aber V: The relationship between regional variations in blood flow and histology in a transplanted rat fibrosarcoma. Br J Cancer 61: 250–257, 1990
Jain RK: Transport of molecules across tumor vasculature. Cancer Metastasis Rev 6: 559–593, 1987
Suzuki M, Hori M, Abe I, Sachiko S, Sato H: Functional characterization of the microcirculation in tumors. Cancer Metastasis Rev 3: 115–126, 1984
Fidler IJ: Macrophages and metastasis: a biological approach to cancer therapy. Cancer Res 45: 4714–4726, 1985
Bradley G, Juranka PE, Ling V: Mechanism of multidrug resistance. Biochim Biophys Acta 948: 87–128, 1988
Rothenberg M, Ling V: Multidrug resistance: molecular biology and clinical relevance. J Natl Cancer Inst 81: 907–910, 1989
Pastan I, Gottesman MM, Ueda K, Lovelace E, Rutherford AV, Willingham MC: A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Acad Sci USA 85: 4486–4490, 1988
Croop JM, Gros P, Housman DE: Genetics of multidrug resistance. J Clin Invest 81: 1303–1309, 1988
Kanamaru H, Kakehi Y, Yoshida O, Nakanishi S, Pastan I, Gottesman MM: MDR1 RNA levels in human renal cell carcinomas: correlation with grade and prediction of reversal of doxorubicin resistance by quinidine in tumor explants. J Natl Cancer Inst 81: 844–849, 1989
Kartner N, Riordan JR, Ling V: Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 221: 1285–1288, 1983
Chabner BA, Fogi A: Multidrug resistance: P-glycoprotein and its allies - the elusive foes. J Natl Cancer Inst 81: 910–913, 1989
Koch G, Smith M, Twentyman P, Wright K: Identification of a novel calcium-binding protein (CP22) in multidrug-resistant murine and hamster cells. FEBS Lett 195: 275–279, 1986
Hamada H, Okochi E, Oh-hara T, Tsuruo T: Purification of the Mr 22,000 calcium-binding protein (sorcin) associated with multidrug resistance and its detection with monoclonal antibodies. Cancer Res 48: 3173–3178, 1988
Deffie AM, Alam T, Seneviratne C, Beenken SW, Batra JK, Shea TC, Henner WS, Goldenberg GJ: Multifactorial resistance to Adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of Adriamycin-sensitive and -resistant P388 leukemia. Cancer Res 48: 3595–3602, 1988
Tsuruo T, Iida H, Kawabara H, Tsukagoshi S, Sakurai Y: High calcium content of pleiotropic drug-resistant P388 and K562 leukemia and Chinese hamster ovary cells. Cancer Res 44: 5095–5099, 1984
Nair S, Samy TS, Krishan A: Calcium, calmodulin, and protein content of Adriamycin-resistant and -sensitive murine leukemia cells. Cancer Res 46: 229–232, 1986
Baskin F, Rosenberg RN, Dev V: Correlation of doubleminute chromosomes with unstable multidrug cross-resistance in uptake mutants of neuroblastoma cells. Proc Natl Acad Sci USA 78: 3654–3658, 1981
O'Brian CA, Ward NE: Biology of the protein kinase C family. Cancer Metastasis Rev 8: 199–214, 1989
O'Brian CA, Fan D, Ward NE, Seid C, Fidler IJ: Level of protein kinase C activity correlates directly with resistance to Adriamycin in murine fibrosarcoma cells. FEBS Letts 246: 78–82, 1989
Zwelling LA, Michaels S, Erickson LC, Ungeleier RS, Nichols M, Kohn K: Protein-associated DNA breaks in L1210 cells treated with the DNA intercalating agents 4'-(9-acridinylamino)-methanesulfon-m-anisidide and Adriamycin. Biochemistry 20: 6553–6563, 1981
Glisson B, Gupta R, Hodges R, Ross W: Cross-resistance to intercalating agents in an epipodophyllotoxin-resistant Chinese hamster ovary cell line: evidence for a common intracellular target. Cancer Res 46: 1931–1941, 1986
Tsuruo T: Mechanisms of multidrug resistance and implications for chemotherapy. Jpn J Cancer Res 79: 285–296, 1988
Redmond SMS, Joncourt F, Buser K, Ziemiecki A, Altermatt H-J, Fey M, Margison G, Cerny T: Assessment of P-glycoprotein, glutathione-based detoxifying enzymes, and O6-alkylguanine-DNA alkyltransferase as potential indicators of constitutive drug resistance in human colorectal tumors. Cancer Res 51: 2092–2097, 1991
Deuchars KL, Ling V: P-glycoprotein and multidrug-resistance in cancer chemotherapy. Semin Oncol 16: 156–165, 1989
Staroselsky A, Fan D, O'Brian CA, Gupta KP, Fidler IJ: Site-dependent differences in response of the UV-2237 murine fibrosarcoma to systemic therapy with Adriamycin. Cancer Res 40: 7775–7780, 1990
Houghton PJ, Tew KD, Taylor DM: Some studies of the distribution and effects of cyclophosphamide in normal and neoplastic tissue. Cancer Treat Rep 60: 459–464, 1976
Kripke ML, Gruys E, Fidler IJ: Metastatic heterogeneity of cells from an ultraviolet light-induced murine fibrosarcoma of recent origin. Cancer Res 38: 2962–2967, 1978
Radinsky R: Growth factors and their receptors in metastasis. Semin Cancer Biol 2: 169–177, 1991
Rice GC, Ling V, Schimke RT: Frequencies of independent and simultaneous selection of Chinese hamster cells for methotrexate and doxorubicin (Adriamycin) resistance. Proc Natl Acad Sci USA 84: 9261–9264, 1987
Roizin-Towle L, Hall EJ: Studies with bleomycin and misonidasole on aerated and hypoxic cells. Br J Cancer 37: 254–260, 1978
Smith E, Stratford IJ, Adam GE: Cytotoxicity of Adriamycin on aerobic and hypoxic Chinese hamster cellsin vitro. Br J Cancer 41: 569–573, 1980
Tannock I, Guttman P: Response of Chinese hamster ovary cells to anticancer drugs under aerobic and hypoxic conditions. Br J Cancer 43: 245–248, 1981
Fan D, Morgan LR, Schneider C, Blank H, Roy S, Wang YF, Fan S: Pharmacologic assessment of regimen chemosensitivity in soft agar assay: effect of oxygen on human tumors. J Cancer Res Clin Oncol 110: 209–215, 1985
Richter A, Sanford KK, Evans VJ: Influence of oxygen and culture media on plating efficiency of some mammalian tissue cells. J Natl Cancer Inst 49: 1705–1712, 1972
Pritsos CA, Sartorelli AS: Generation of reactive oxygen radicals through bioactivation of mitomycin antibiotics. Cancer Res 46: 3528–3532, 1986
Oberley LW, Buettne GR: Role of superoxide dismutase in cancer: a review. Cancer Res 39: 1141–1149, 1979
Bachur NR, Gordon SL, Gee MV, Kon H: NADPH-cytochrome P-450 reductase activation of quinone anticancer agents to free radicals. Proc Natl Acad Sci USA 76: 954–957, 1979
Giavazzi R, Miller L, Hart IR: Metastatic behavior of an Adriamycin-resistant murine tumor. Cancer Res 43: 5081–5086, 1986
Fidler IJ: Rationale and methods for the use of nude mice to study the biology and therapy of human cancer metastasis. Cancer Metastasis Rev 5: 29–49, 1986
Morikawa K, Walker SM, Jessup JM, Fidler IJ:In vivo selection of highly metastatic cells from surgical specimens of different human colon carcinomas implanted into nude mice. Cancer Res 48: 1943–1948, 1988
Morikawa K, Walker SM, Nakajima M, Pathak S, Jessup JM, Fidler IJ: The influence of organ environment on the growth, selection, and metastasis of human colon cancer cells in nude mice. Cancer Res 48: 6363–6871, 1988
DeVore DP, Houchens DP, Ovejera AA, Dill Jr GS, Hutson TB: Collagenase inhibitors retarding invasion of a human tumor in nude mide. Exp Cell Biol 48: 367–373, 1980
Nakajima M, Chop AM: Tumor invasion and extracellular matrix degradative enzymes: regulation of activity by organ factors. Semin Cancer Biol 2: 115–127, 1991
Nakajima M, Morikawa K, Fabra A, Bucana CD, Fidler IJ: Influence of organ environment on extracellular matrix degradative activity and metastasis of human colon carcinoma cells. J Natl Cancer Inst 82: 1890–1898, 1990
Fabra A, Nakajima M, Bucana CD, Fidler IJ: Modulation of the invasive phenotype of human colon carcinoma cells by organ-specific fibroblasts of nude mice. Differentiation 52: 101–110, 1992
August DA, Ottow RT, Sugarbaker PH: Clinical perspective of human colorectal cancer metastasis. Cancer Metastasis Rev 3: 303–324, 1984
Kemeny N: Role of chemotherapy in the treatment of colorectal carcinoma. Semin Surg Oncol 3: 190–214, 1987
Wilmanns C, Fan D, O'Brian CA, Radinsky R, Bucana CD, Tsan R, Fidler IJ: Modulation of doxorubicin sensitivity and level of P-glycoprotein expression in human colon carcinoma cells by ectopic and orthotopic environments in nude mice. Int J Oncol 3: 413–422, 1993
Wolfman A, Wingrove IG, Blackshear PJ, Macara IG: Downregulation of protein kinase C and of an endogenous 80-kDa substrate in transformed fibroblasts. J Biol Chem 2672: 16546–16552, 1987
Weyman CM, Taparowsky EJ, Woltson J, Ashendel CL: Partial downregulation of protein kinase C in C3H 10T1/2 mouse fibroblasts transfected with the human Ha-ras oncogene. Cancer Res 48: 6535–6541, 1988
Guillem JG, O'Brian CA, Fitzer CJ, Forde KA, LoGerfo P, Treat M, Weinstein IB: Altered levels of protein kinase C and Ca2+-dependent protein kinases in human colon carcinomas. Cancer Res 47: 2036–2039, 1987
Tsuruo T: Mechanisms of multidrug resistance and implication for therapy. Jpn J Cancer Res 79: 285–296, 1988
Deuchars KL, Ling V: P-glycoprotein and multidrug resistance in cancer chemotherapy. Semin Oncol 16: 156–165, 1989
Moscow JA, Cowan KH: Multidrug resistance. J Natl Cancer Inst 80: 14–20, 1988
Gottesman MM, Pastan I: The multidrug transporter, a double-edged sword. J Biol Chem 263: 12163–12166, 1988
Weinstein RS, Kuszak IR, Kluskens LF, Con JS: P-glycoprotein in pathology: the multidrug resistance gene family in humans. Hum Pathol 21: 34–48, 1990
Melamed MR: Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38: 1277–1287, 1990
Charcasset JY, Alard C, Brousset P, Mazarolles C, Delsol G: Immunohistochemical detection of multidrug resistance-associated P-glycoprotein in tumor and stromal cells of human cancers.Br J Cancer 62: 177–182, 1990
Thorgeirsson SS, Huber BE, Sorell S, Fojo A, Pastan I, Gottesman MM: Expression of the multidrug-resistant gene in hepatocarcinogenesis and regenerating rat liver. Science 236: 1120–1122, 1987
Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I: Expression of a multidrug resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84: 265–269, 1987
Shimazu H, Tsuruo T, Sumizawa T, Akiyama S: Expression of themdr1 gene in human gastric antral carcinomas. J Natl Cancer Inst 82: 1679–1683, 1990
Shen DW, Fojo A, Chin IE, Ronninson B, Richert N, Pastan I, Gottesman MM: Human multidrug resistant cell lines: increasedmdr1 expression can precede gene amplification. Science 232: 634–645, 1986
Wilmanns C, Fan D, O'Brian CA, Bucana CD, Fidler IJ: Orthotopic and ectopic organ environments differentially influence the sensitivity of murine colon carcinoma cells to doxorubicin and 5-fluorouracil. Int J Cancer 52: 98–104, 1992
Pastan I, Gottesman M: Multiple resistance in human cancer. New Engl J Med 316: 1388–1393, 1987
Deffie AM, Alam T, Seneviratne C, Beenken SW, Batra IK, Shea TC, Henner WD, Goldenberg GJ: Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia. Cancer Res 48: 3595–3602, 1988
Redmond SMS, Joncourt F, Buser K, Ziemiecki A, Altermatt H-J, Fey M, Margison G, Cerny T: Assessment of P-glycoprotein, glutathione-based detoxifying enzymes, and O6-alkylguanine-DNA alkyltransferase as potential indicators of constitutive drug resistance in human colorectal tumors. Cancer Res 51: 2092–2097, 1991
Berger SH, Jenh C-H, Johnson LF, Berger FG: Thymidilate synthetase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells. Molec Pharmacol 28: 461–467, 1985
Deuchars KL, Ling V: P-glycoprotein and multidrug resistance in cancer chemotherapy. Semin Oncol 16: 156–165, 1989
Hutchinson DJ: Modes of acquiring resistance to antineoplastic agents. In: Berkada B, Karrer K, Mathe G (eds) Clinical Chemotherapy, vol 3. Thieme-Straton, New York, 1984, pp 368–383
Fan D, Wilmanns C, O'Brian CA, Kuo MT, Teeter LD, Bucana CD, Ward NE, Fidler IJ: Orthotopic and ectopic modulation of P-glycoprotein and resistance to adriamycin of human colon carcinoma cells in nude mice. Proc Amer Assn Cancer Res 33: 468, 1992
Sartorelli AC: Therapeutic attack of hypoxic cells of solid tumors: presidential address. Cancer Res 48: 775–778, 1988
Tannock IF, Van Rotin D: Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 49: 4373–7384, 1989
Collins JM: Pharmacokinetics of 5-fluorouracil infusions in the rat: comparison with man and other species. Cancer Chemother Pharmacol 14: 108–111, 1985
Reddy BS, Watanabe K, Weisburger JH, Wynder EL: Promoting effect of bile acids in colon carcinogenesis in germfree and conventional F344 rats. Cancer Res 37: 3238–3242, 1977
Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Pirker R, Green A, Grist W, Brodeur GM, Lieber M, Cossman J, Gottesman MM, Pastan I: Expression of a multidrug resistance gene in human tumors. J Natl Cancer Inst 81: 116–124, 1989
Weinstein RS, Jakate SM, Dominguez JM, Lebovitz MD, Koukoulis GK, Kuszak JR, Klusens LF, Grogen TM, Saclarides TJ, Roninson IB, Coon JS: Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 51: 2720–2726, 1991
Fojo AT, Ueda K, Slamon DJ, Poplack D, Gottesman MM, Pastan I: Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84: 265–269, 1987
Park JG, Kramer BS, Lai SL, Goldstein LJ, Gazdar AF: Chemosensitivity patterns and expression of human multidrug resistance-associated MDR1 gene by human gastric and colorectal carcinoma cell lines. J Natl Cancer Inst 82: 193–198, 1990
Raghu G, Pierre-Jerome J, Dordal MS, Simonian P, Bauer KD, Winter JW: P-glycoprotein and alterations in the glutathione/glutathione-peroxidase cycle underlie doxorubicin resistance in HL-60-R, a subclone of the HL-60 human leukemia cell line. Int J Cancer 53: 804–811, 1993
Mattern MVJ, Pomerenke EW: Time course of MDR gene amplification duringin vivo selection for doxorubicin-resistance and during reversal in murine leukemia L1210. Anticancer Res 11: 579–586, 1991
Thorgeirsson SS, Huber BE, Sorrell S, Fojo SA, Pastan I, Gottesman MM: Expression of the multidrug-resistant gene in hepatocarcinogenesis and regenerating rat liver. Science 236: 1120–1122, 1987
Marino PA, Gottesman MM, Pastan I: Regulation of the multidrug resistance gene in regenerating rat liver. Cell Growth Differ 1: 57–62, 1990
Michalopoulos GK: Liver regeneration: molecular mechanisms of growth control. FASEB J 4: 176–187, 1990
Mead JE, Fausto N: Transforming growth factor α may be a physiological regulator of liver regeneration by means of an autocrine mechanism. Proc Natl Acad Sci USA 86: 1558–1562, 1989
Gherardi E, Stoker M: Hepatocyte growth factor-scatter factor: Mitogen, motogen, andmet. Cancer Cells 3: 227–232, 1991
Cornwell MM, Smith DE: A signal transduction pathway for activation of themdr1 promoter involves the protooncogene c-raf kinase. J Biol Chem 268: 15347–15350, 1993
Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller Jr WH, Mendelsohn J: Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 85: 1327–1333, 1993
Radinsky R: Paracrine growth regulation of human colon carcinoma organ-specific metastases. Cancer Metastasis Rev 12: 345–361, 1993
Schuetz JD, Schuetz EG: Extracellular matrix regulation of multidrug resistance in primary monolayer cultures of adult rat hepatocytes. Cell Growth Differ 4: 31–40, 1993
Chin K, Tanaka S, Darlington G, Pastan I, Gottesman MM: Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human renal carcinoma cells. J Biol Chem 265: 221–226, 1990
Fairchild CR, Ivy SP, Rushmore T, Lee G, Koo P, Goldsmith M, Myers C, Farber E, Cowan K: Carcinogen-induced mdr overexpression is associated with xenobiotic resistance in rat preneoplastic liver nodules and hepatocellular carcinomas. Proc Natl Acad Sci USA 84: 7701–7705, 1987
Chin K-V, Pastan I, Gottesman MM: Function and regulation of the human multidrug resistance gene. Adv Cancer Res 60: 1157–1180, 1993
Chin K-V, Chauhan SS, Pastan I, Gottesman MM: Regulation ofmdr1 RNA levels in response to cytotoxic drugs in rodent cells. Cell Growth Differen 1: 361–365, 1990
Kohno K, Sato S, Takano H, Matsuo K, Kuesno M: The direct activation of human multidrug resistance gene (MDR1) by anticancer agents. Biochem Biophys Res Commu 165: 1415–1421, 1989
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fidler, I.J., Wilmanns, C., Staroselsky, A. et al. Modulation of tumor cell response to chemotherapy by the organ environment. Cancer Metast Rev 13, 209–222 (1994). https://doi.org/10.1007/BF00689637
Issue Date:
DOI: https://doi.org/10.1007/BF00689637